AAV-based pulmonary gene delivery may support new therapeutic strategies for inherited and chronic respiratory diseases

As gene therapy continues to advance, adeno-associated virus, or AAV, is being explored as a potential delivery platform for lung-directed therapies. The lung is central to respiration, gas exchange, immune defense, and overall quality of life. Diseases such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, and acute or chronic inflammatory lung injury remain major global health challenges. For many of these conditions, current treatments can reduce symptoms or slow disease progression, but they often do not correct the underlying molecular causes.

AAV-based lung gene therapy aims to deliver therapeutic genetic material directly to airway or alveolar cells. In principle, this approach could support long-term local expression of a therapeutic protein, gene replacement for inherited lung disorders, gene silencing for harmful pathways, or delivery of anti-inflammatory and tissue-protective factors. However, pulmonary AAV delivery remains more challenging than AAV delivery to some other organs, and many applications are still in the preclinical or early translational stage.

Why AAV Is Being Explored for Lung Gene Therapy

AAV vectors are attractive for gene therapy because they can mediate gene transfer in non-dividing cells, support relatively long-term transgene expression, and can be engineered through serotype selection or capsid modification to improve tissue tropism. For lung applications, AAV may be delivered by inhalation, intranasal administration, intratracheal delivery, or other localized routes, depending on the target cell population and disease model.

Potential advantages of AAV for lung-directed therapy include:

• Local delivery to the respiratory tract, which may reduce systemic exposure compared with intravenous administration.
• Possibility of durable expression in long-lived airway or alveolar cells.
• Flexible vector design for gene replacement, gene silencing, genome editing support, or delivery of protective proteins.
• Compatibility with engineered capsids and cell-type-specific promoters to improve targeting.
• Potential use in both inherited and acquired lung disease models.

At the same time, AAV is not automatically efficient in the lung. The respiratory tract has evolved strong physical and immunological barriers against inhaled particles, including mucus, mucociliary clearance, airway surface liquid, epithelial tight junctions, innate immune defenses, and pre-existing anti-AAV immunity. These barriers can limit vector access to target cells and reduce transduction efficiency. Reviews of inhaled gene therapy emphasize that delivery across the airway surface remains one of the key obstacles for respiratory gene transfer. (pmc.ncbi.nlm.nih.gov)

Inherited Lung Diseases: Cystic Fibrosis and Beyond

Cystic fibrosis is one of the most important inherited lung diseases considered for gene therapy. It is caused by pathogenic variants in the CFTR gene, leading to abnormal chloride and bicarbonate transport, dehydrated airway mucus, chronic infection, inflammation, and progressive lung damage. A gene replacement strategy could, in theory, deliver a functional CFTR gene to airway epithelial cells.

AAV has been tested in cystic fibrosis research, including early clinical studies of aerosolized AAV-CFTR. These studies helped demonstrate the feasibility and general tolerability of repeated aerosolized AAV delivery, but they did not produce significant sustained improvement in lung function. One key limitation is that the full-length CFTR coding sequence is large and difficult to package efficiently within the limited AAV genome capacity, which is approximately 4.7 kb. (pubmed.ncbi.nlm.nih.gov)

As a result, current cystic fibrosis gene therapy research includes multiple delivery strategies, including lentiviral vectors, non-viral nanoparticles, mRNA delivery, gene editing, and improved AAV-based approaches. For AAV, future progress may depend on compact CFTR constructs, dual-vector systems, engineered capsids with better airway tropism, and improved delivery methods. Recent reviews describe cystic fibrosis gene therapy as promising but still challenged by delivery efficiency, durability, immune response, and disease-relevant target-cell access. (pmc.ncbi.nlm.nih.gov)

Chronic Lung Diseases: COPD, Asthma, and Inflammatory Pathways

Chronic obstructive pulmonary disease, or COPD, is a complex disease involving chronic inflammation, airway remodeling, emphysema, mucus hypersecretion, and impaired lung function. Unlike monogenic diseases such as cystic fibrosis, COPD is not caused by a single gene defect. Therefore, AAV-based strategies for COPD would likely focus on modifying disease pathways rather than replacing one missing gene.

Potential research directions include delivery of anti-inflammatory factors, antioxidant proteins, protease inhibitors, tissue-protective molecules, or gene-silencing tools targeting mucus overproduction or inflammatory mediators. Similar concepts are being explored in asthma and other chronic airway diseases. For example, preclinical studies have investigated AAV-mediated delivery of RNA interference tools to suppress mucus-associated genes such as MUC5AC, which is involved in airway mucus hypersecretion. (pmc.ncbi.nlm.nih.gov)

These approaches remain investigational. Because chronic lung diseases are biologically complex and heterogeneous, therapeutic success will require precise target selection, appropriate patient stratification, efficient delivery to the relevant lung cell types, and strong evidence that modifying a pathway produces meaningful clinical benefit.

Key Delivery and Development Challenges

Lung-directed AAV therapy faces several major barriers that must be addressed before broad clinical translation. The first is delivery efficiency. Inhaled or airway-delivered vectors must pass through mucus, avoid rapid clearance, reach the correct epithelial or alveolar cells, and enter cells efficiently. In diseased lungs, mucus obstruction, inflammation, infection, and tissue remodeling may further reduce vector distribution.

The second challenge is vector design. Different AAV serotypes vary in their ability to transduce airway epithelial cells, alveolar cells, immune cells, and other lung cell populations. Engineered capsids may improve tropism, but they must also be evaluated for manufacturability, potency, biodistribution, and immune recognition.

The third challenge is payload size. AAV has a limited packaging capacity, which complicates delivery of large genes such as CFTR or complex gene editing systems. Compact promoters, optimized regulatory elements, split-vector systems, or alternative delivery technologies may be required.

Other key challenges include:

• Pre-existing neutralizing antibodies against AAV capsids.
• Local airway inflammation after vector administration.
• Need for repeat dosing in some chronic diseases.
• Variable transduction across airway regions and cell types.
• Differences between animal models and human lung anatomy.
• Manufacturing requirements for high-quality, well-characterized AAV vectors.

Future Outlook

AAV lung gene therapy remains an emerging field, but advances in vector engineering are expanding its potential. Next-generation capsids, improved inhalation delivery devices, tissue-specific promoters, optimized expression cassettes, and better preclinical models may help overcome current barriers. In the future, AAV may be used not only for gene replacement in inherited lung diseases, but also for localized delivery of therapeutic proteins, RNA-based tools, or genome editing components in selected respiratory disorders.

Progress will likely depend on matching the right vector design to the right disease biology. For monogenic diseases, this may mean efficient delivery of a functional gene or editing system to airway stem or progenitor cells. For chronic inflammatory diseases, it may mean local, controlled modulation of specific pathways without broadly suppressing host defense.

Conclusion

AAV-based lung gene therapy offers an innovative but still developing approach for respiratory disease treatment. Its potential lies in durable, localized gene delivery to lung tissues, with possible applications in inherited disorders such as cystic fibrosis and in selected chronic inflammatory or obstructive lung diseases.

However, pulmonary delivery presents unique challenges, including mucus barriers, immune defenses, limited payload capacity, variable tissue tropism, and the need for clinically meaningful long-term expression. Continued advances in AAV capsid engineering, delivery technology, cassette design, and pulmonary disease modeling will be essential for translating this promising platform into effective therapies for lung disease.

How PackGene Supports AAV Lung Gene Therapy Research

PackGene provides customized AAV solutions to support lung-directed gene therapy research and preclinical development, including vector design, plasmid construction, AAV production, purification, serotype selection, capsid evaluation, and analytical testing. For pulmonary applications, PackGene can help researchers develop fit-for-purpose AAV vectors with appropriate promoters, payload designs, serotypes, and quality control strategies for in vitro and in vivo respiratory disease studies.

By combining flexible AAV vector design, scalable production workflows, and quality-focused analytical characterization, PackGene supports researchers exploring AAV-based approaches for inherited lung diseases, inflammatory airway disorders, pulmonary injury models, and other respiratory research applications.